# Zealthy Expands Online Access to Ozempic Evaluations and Insurance Support for Eligible Patients With Type 2 Diabetes

Page: https://stenobird.com/podcast/global-economic-press-7086730/zealthy-expands-online-access-to-ozempic-evaluations-and-insurance-support-for-eligible-patients-with-type-2-diabetes
Text version: https://stenobird.com/podcast/global-economic-press-7086730/zealthy-expands-online-access-to-ozempic-evaluations-and-insurance-support-for-eligible-patients-with-type-2-diabetes.md
Podcast: [Global Economic Press](https://stenobird.com/podcast/global-economic-press-7086730)
Published: 2026-06-23T21:43:14+00:00
Episode link: https://global-economic-press.podbean.com/e/zealthy-expands-online-access-to-ozempic-evaluations-and-insurance-support-for-eligible-patients-with-type-2-diabetes/
Audio file: https://mcdn.podbean.com/mf/web/43v47wo4c97zu374/press_release_12458_1782250985.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/global-economic-press-7086730/episodes/zealthy-expands-online-access-to-ozempic-evaluations-and-insurance-support-for-eligible-patients-with-type-2-diabetes
Duration seconds: 990

## Resource

In this episode of Global Economic Press, Alex Brady explores the innovative telehealth platform Zealthy and its recent expansion to provide online access to Ozempic evaluations and insurance support for eligible patients with Type 2 Diabetes. Zealthy connects patients with licensed healthcare providers, offering a convenient alternative to traditional in-person appointments. The platform allows patients to complete medical assessments from home, receive guidance on medication eligibility, and manage prescriptions and insurance coordination. This expansion aims to transform diabetes management by making it more accessible and efficient for patients. Zealthy's program offers a comprehensive approach, including remote medical evaluations, ongoing provider support, and assistance with insurance and prior-authorization processes. While the introductory membership fee is $39, patients should be aware of the regular $135 monthly membership cost and the separate expense of Ozempic, which may be reduced by insurance coverage. It is crucial to note that Ozempic is primarily a diabetes medication, not an FDA-approved weight-loss drug. Patients interested in weight management should consider other options like Wegovy. For more information about Zealthy and its services, visit their website at Zealthy.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/global-economic-press-7086730/episodes/zealthy-expands-online-access-to-ozempic-evaluations-and-insurance-support-for-eligible-patients-with-type-2-diabetes/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/global-economic-press-7086730/zealthy-expands-online-access-to-ozempic-evaluations-and-insurance-support-for-eligible-patients-with-type-2-diabetes.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.